Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates
Skip to main content Advertisement Advertisement Advertisement Advertisement Turn static files into dynamic content formats
Wang L, Prescott AR, Spruce BA, Sanderson J, Duncan G
GLP-1s, a class of drugs used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have exploded in popularity in recent years due to their demonstrated effectiveness, but are often not covered by insurance, particularly for the treatment of obesity
US$ 28.36
US$ 22.58
US$ 23.62
US$ 21.02
